Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Monday April 15 2019, @10:22PM   Printer-friendly
from the YADIDNKE-Yet-Another-Disease-I-Did-Not-Know-Existed dept.

Promising Results with Givosiran in Acute Hepatic Porphyrias[*]

Investigational givosiran met the primary endpoint of reduction in the annualized rate of composite porphyria attacks versus placebo in patients with acute hepatic porphyria (AHP), researchers said here.

In the interim analysis of the phase III ENVISION trial, patients treated with givosiran experienced a mean composite annualized rate of 3.2 attacks versus 12.5 attacks in patients on placebo (P<0.0001), for a mean reduction of 74%, said Manisha Balwani, MD, of the Mount Sinai School of Medicine in New York City, and colleagues.

"We saw a robust treatment effect," said Balwani at a press conference at the European Association for the Study of the Liver (EASL) annual meeting.

"Currently, there are no approved therapies aimed at preventing the painful, often incapacitating attacks, and chronic symptoms associated with acute hepatic porphyria," she added. "The results from ENVISION are promising and demonstrate a strong treatment effect for givosiran, with reduction of attacks and improvement in patient-reported measures of overall health status and quality of life."

[*] Porphyria.

BBC has a dumbed down article: Gene-silencing: 'New class' of medicine reverses disease porphyria


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Monday April 15 2019, @11:01PM

    by Anonymous Coward on Monday April 15 2019, @11:01PM (#830152)

    Your days of evil-doing are coming to an end, even if the summary doesn't bother to tell us what you are.